NCT06818838View on ClinicalTrials.gov

A Clinical Study Evaluating LY-M001 Injection in the Treatment of Adult Patients With Type I Gaucher Disease

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

July 5, 2024

Primary Completion Date

July 30, 2027

Study Completion Date

July 30, 2031

Conditions
Gaucher Disease Type 1
Interventions
BIOLOGICAL

LY-M001 injection

LY-M001 injection is administered intravenously as a single dose

Trial Locations (1)

300011

RECRUITING

Hematology Hospital, Chinese Academy of Medical Sciences, Tianjin

All Listed Sponsors
lead

Lingyi Biotech Co., Ltd.

INDUSTRY